RT Journal Article
SR Electronic
T1 Clinical-grade whole genome sequencing-based haplarithmisis enables all forms of preimplantation genetic testing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.06.23299605
DO 10.1101/2023.12.06.23299605
A1 Janssen, Anouk E.J.
A1 Koeck, Rebekka M.
A1 Essers, Rick
A1 van Dijk, Wanwisa
A1 Drüsedau, Marion
A1 Meekels, Jeroen
A1 Yaldiz, Burcu
A1 van de Vorst, Maartje
A1 Cao, Ping
A1 de Koning, Bart
A1 Hellebrekers, Debby M.E.I.
A1 Stevens, Servi J.C.
A1 Sun, Su Ming
A1 Heijligers, Malou
A1 de Munnik, Sonja A.
A1 van Uum, Chris M.J.
A1 Achten, Jelle
A1 Hamers, Lars
A1 Naghdi, Marjan
A1 Vissers, Lisenka E.L.M.
A1 van Golde, Ron J.T.
A1 de Wert, Guido
A1 Dreesen, Jos C.F.M.
A1 de Die-Smulders, Christine
A1 Coonen, Edith
A1 Brunner, Han G.
A1 van den Wijngaard, Arthur
A1 Paulussen, Aimee D.C.
A1 Esteki, Masoud Zamani
YR 2023
UL http://medrxiv.org/content/early/2023/12/08/2023.12.06.23299605.abstract
AB High-throughput sequencing technologies have increasingly led to discovery of disease-causing genetic variants, primarily in postnatal multi-cell DNA samples. However, applying these technologies to preimplantation genetic testing (PGT) in nuclear or mitochondrial DNA from single or few-cells biopsied from in vitro fertilised (IVF) embryos is challenging. PGT aims to select IVF embryos without genetic abnormalities. Although genotyping-by-sequencing (GBS)-based haplotyping methods enabled PGT for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), and aneuploidies (PGT-A), they are labour intensive, only partially cover the genome and are troublesome for difficult loci and consanguineous couples. Here, we devised a simple, scalable and universal whole genome sequencing haplarithmisis-based approach enabling all forms of PGT in a single assay. In a comparison to state-of-the-art GBS-based PGT for nuclear DNA (37 embryos, 18 families, 25 indications), shallow sequencing-based PGT (10 embryos, 3 families), and PCR-based PGT for mitochondrial DNA (10 embryos, 2 families), our approach alleviates technical limitations by decreasing whole genome amplification artifacts by 68.4%, increasing breadth of coverage by 4-fold, and reducing wet-lab turn-around-time by 2.5-fold. Importantly, this method enables trio-based PGT-A for aneuploidy origin, an approach we coin PGT-AO, detects translocation breakpoints, and nuclear and mitochondrial single nucleotide variants and indels in base-resolution.Competing Interest StatementM.Z.E. is co-inventor on patent applications: ZL910050-PCT/EP2011/ 060211-WO/2011/157846 'Methods for haplotyping single cells' and ZL913096-PCT/EP2014/068315-WO/2015/028576 'Haplotyping and copy-number typing using polymorphic variant allelic frequencies'.Funding StatementThis study was funded by The EVA (Erfelijkheid Voortplanting & Aanleg) specialty program (grant no. KP111513), the Horizon Europe (NESTOR, grant no. 101120075) of the European Commission and the Horizon 2020 innovation (ERIN, grant no. EU952516) grants.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Full ethics committee approval was not required owing to the retrospective design of the study and the anonymized handling of the data under file number 2023-0091 titled "Development of integrative methods for IVF embryo selection", from the ethics committee from the Maastricht UMC+.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe whole genome sequencing data cannot be shared publicly to protect the privacy of the families that participated in the study. The anonymised data may be requested through the corresponding author and via application to data access committee of MUMC+. Processed data presented in this paper, is submitted as Supplementary Table 9.